• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Rogers Corporation

Rogers Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Roche: Zelboraf Study Failed to Meet Endpoint

    Roche: Zelboraf Study Failed to Meet Endpoint

  2. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

  3. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

  4. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

  5. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

  6. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to be priced based on cancer patients' outcomes

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to be priced based on cancer patients' outcomes

  7. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

  8. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

  9. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

12345

©2017 Morningstar Advisor. All right reserved.